Avego BioScience Capital

Funding rounds backed by Avego BioScience Capital.

Export CSV
Funding disclosed in full
$377M
Median round
$107M
Rounds in calculation
3
3 rounds
LatestLargest
Funding rounds with company descriptions, amounts, stages and announcement dates
CompanyRoundMarketInvestorsAnnouncedDetails
CellCentric

Develops inobrodib, a first-in-class oral p300/CBP inhibitor for relapsed or refractory multiple myeloma

$220MSeries DBiotechUnited Kingdom
9 participantsAmerican Cancer Society BrightEdgeAvego BioScience CapitalFidelity Management & Research CompanyForbionHBM HealthcarePfizerRA Capital ManagementSofinnova PartnersVenrock Healthcare Capital Partners
TRex Bio

Develops precision immunoregulatory medicines based on tissue Treg biology

$50MUndisclosedBiotechUnited States
11 participantsAffinity Asset AdvisorsAlexandria Venture InvestmentsAvego BioScience CapitalBalyasny Asset ManagementDelos CapitalEli Lilly and CompanyJanus Henderson InvestorsJohnson & Johnson Innovation – JJDCPfizer VenturesPolaris PartnersSV Health Investors
EpiBiologics

Develops novel bispecific antibodies for targeted degradation of extracellular proteins in oncolo...

$107MSeries BBiotechUnited States
13 participantsAulis CapitalAvego BioScience CapitalCodon CapitalDigitalis VenturesGV (Google Ventures)IncJohnson & Johnson Innovation – JJDCMission BioCapitalNovartis Venture Fund (NVF)Polaris PartnersSamsara BioCapitalTaiho VenturesVivo Capital